Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | MGAM | O43451 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SI | P14410 | 1/20 | 0.45 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5261760 | 0.98 | GPR84 (0.46) | GPR84SRCCYP2D6KCNH2MAPT | |
| SCHEMBL28093308 | 0.88 | P4HB (0.44) | GPR84MAPTFFAR1GAAMEN1 | |
| SCHEMBL28293968 | 0.85 | NR3C1 (0.61) | SRCCYP2D6MAPTNR3C1PGR | |
| SCHEMBL28295738 | 0.81 | OPRL1 (0.44) | GPR84CYP2D6MAPTFFAR1MEN1 | |
| SCHEMBL28295795 | 0.80 | P4HB (0.49) | GPR84SRCMAPTNR3C1PGR | |
| SCHEMBL5259231 | 0.77 | TRPM8 (0.50) | MAPTSLC6A4GAAMEN1KMT2A | |
| SCHEMBL9456621 | 0.77 | GPR84 (0.54) | GPR84SRCCYP2D6MAPTFFAR1 | |
| SCHEMBL6985439 | 0.77 | MAPK1 (0.48) | GPR84CYP2D6MAPTFFAR1MEN1 | |
| SCHEMBL5261272 | 0.76 | TRPM8 (0.49) | MAPTSLC6A4GAAMEN1KMT2A | |
| SCHEMBL2054235 | 0.74 | CYP2D6 (0.67) | CYP2D6KCNH2MAPTSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109645008-A | The application of donaxine and its derivative in Antiphytoviral and germ | 河北工业大学 | 2019-04-19 | — | — | CN | claimed |
| EP-1261585-B1 | SUBSTITUTED INDOLE MANNICH BASES | GRUENENTHAL GMBH (DE) | 2007-09-26 | — | — | EP | claimed |
| US-7091220-B2 | Substituted indole Mannich bases | GRUENENTHAL GMBH (DE) | 2006-08-15 | — | — | US | claimed |
| CN-109645008-A | The application of donaxine and its derivative in Antiphytoviral and germ | 河北工业大学 | 2019-04-19 | — | — | CN | disclosed |
| EP-1261585-B1 | SUBSTITUTED INDOLE MANNICH BASES | GRUENENTHAL GMBH (DE) | 2007-09-26 | — | — | EP | disclosed |
| EP-1261585-B1 | SUBSTITUTED INDOLE MANNICH BASES | GRUENENTHAL GMBH (DE) | 2007-09-26 | — | — | EP | disclosed |
| US-7091220-B2 | Substituted indole Mannich bases | GRUENENTHAL GMBH (DE) | 2006-08-15 | — | — | US | disclosed |
| US-20030060497-A1 | Subtituted indole mannich bases | GRUENENTHAL GMBH (DE) | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060497-A1 | Subtituted indole mannich bases | TPH1, IDO1, TPH2 | GPR84 1801/4885SRC 1551/4885CYP2D6 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.